Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Nab-Rapamycin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Nab-Rapamycin||ABI-009|Nab-sirolimus||mTOR Inhibitor 51 mTORC1 Inhibitor 8||ABI-009 (Nab-Rapamycin) is nanoparticle albumin-bound rapamycin and inhibitor of mTOR that has immunosuppressant and anti-tumor activities (PMID: 24089446).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03463265||Phase II||Lomustine + Nab-Rapamycin Nab-Rapamycin Nab-Rapamycin + Temozolomide Bevacizumab + Nab-Rapamycin||ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma||Recruiting|